4.5 Article

A Phenotypic-Driven Approach for the Diagnosis of WOREE Syndrome

Journal

FRONTIERS IN PEDIATRICS
Volume 10, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fped.2022.847549

Keywords

epilepsy; Exome sequencing (ES); WOREE syndrome; array-CGH analysis; WWOX gene

Categories

Funding

  1. Italian Ministry of Health [RF-2016-02361949]

Ask authors/readers for more resources

This article reports on a boy with a peculiar clinic-radiological pattern supporting the diagnosis of WOREE syndrome. Genetic testing revealed pathogenic variants in the WWOX gene and a deletion mutation. The study highlights the possibility of technical pitfalls in targeted next generation sequencing-based testing and the need for further investigation in selected cases with high clinical suspicion.
BackgroundWOREE syndrome is a rare neurodevelopmental disorder featuring drug-resistant epilepsy and global developmental delay. The disease, caused by biallelic pathogenic variants in the WWOX gene, usually leads to severe disability or death within the first years of life. Clinicians have become more confident with the phenotypic picture of WOREE syndrome, allowing earlier clinical diagnosis. We report a boy with a peculiar clinic-radiological pattern supporting the diagnosis of WOREE syndrome. MethodsDNA was extracted from blood samples of the proband and his parents and subjected to Exome Sequencing (ES). Agarose gel electrophoresis, real-time quantitative PCR (Q-PCR), and array-CGH 180K were also performed. ResultsES detected a pathogenic stop variant (c.790C > T, p.Arg264*) in one allele of WWOX in the proband and his unaffected mother. A 180K array-CGH analysis revealed a 84,828-bp (g.chr16:78,360,803-78,445,630) deletion encompassing exon 6. The Q-PCR product showed that the proband and his father harbored the same deleted fragment, fusing exons 5 and 7 of WWOX. ConclusionsGenetic testing remains crucial in establishing the definitive diagnosis of WOREE syndrome and allows prenatal interventions/parental counseling. However, our findings suggest that targeted Next Generation Sequencing-based testing may occasionally show technical pitfalls, prompting further genetic investigation in selected cases with high clinical suspicion.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available